Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
2,371,778
-
Total 13F shares
-
351,699
-
Share change
-
+172,546
-
Total reported value
-
$833,709
-
Price per share
-
$2.37
-
Number of holders
-
17
-
Value change
-
+$409,291
-
Number of buys
-
11
-
Number of sells
-
4
Institutional Holders of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) as of Q3 2025
As of 30 Sep 2025,
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
351,699 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., DRW Securities, LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, Virtu Financial LLC, GEODE CAPITAL MANAGEMENT, LLC, XTX Topco Ltd, and TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.